tbuckley/cabot-search huggingface dataset:
Murine Leukemias with Insertional Mutations at Lmo2 Are Highly Predicitive of Leukemias Induced Following Gene Therapy in SCID-X1 Patients
Authors: Utpal P. Dave, Keiko Akagi, Rati Tripathi, Susan Cleveland, Mary Thompson, Ming Yi, Robert Stephens, James R. Downing, Nancy Jenkins, Neal G. Copeland
Journal: Blood (2008)
TCT-565 Continuing Dual Antiplatelet Therapy or Not Did Not Influence the Rate of Major Cardiac and Cerebral Adverse Events (MACCE) When Patients Were Free from MACCE during the First Two Years after Everolimus-eluting Stent Implantation
Authors: Daisuke Ueshima, Takashi Ashikaga, Taro Sasaoka, Yu Hatano, Ken Kurihara, Shunji Yoshikawa, Mitsuaki Isobe
Journal: Journal of the American College of Cardiology (2015)
TCT-346 Association between Increased Number of Septal Branches within the Myocardial Bridge and Abnormal Diastolic-Fractional Flow Reserve
Authors: Takumi Kimura, Shigemitsu Tanaka, Kozo Okada, Hideki Kitahara, Yuhei Kobayashi, Yukari Kobayashi, Vedant S. Pargaonkar, Paul Yock, Peter J. Fitzgerald, Yasuhiro Honda, Ian S. Rogers, Jennifer A. Tremmel, Ingela Schnittger
Journal: Journal of the American College of Cardiology (2015)
Perception of cancer-related fatigue: Results of a patient survey
Authors: N. Díaz, S. Menjón, C. Rolfo, P. García-Alfonso, J. Carulla, A. Magro, J. Miramón, C. A. Rodríguez, E. Baró, J. A. Gasquet
Journal: Journal of Clinical Oncology (2008)

20629 Background: Fatigue is one of the cancer-related symptoms that has the greatest impact on patients’ lives. This survey was designed to better understand the functional and psychological impact of fatigue and to determine, according to the patient’s perception, the load of fatigue relative to other symptoms. Methods: A cross-sectional, self-administered survey was conducted from August-October 2007. Patients were ≥18 years old, with a diagnosis of cancer, and had received their last therapy session 2–12 months ago. Demographic and tumor information were collected. The survey included 6 questions about the emotional and social impact of fatigue and the patient’s perception of the oncologist’s response to reports of fatigue. Fatigue impact on emotional well-being was measured by a visual analogue scale (0–100). Questions about functional and social impact were rated on a 5-point Likert scale. Descriptive statistics were used to summarize demographic variables and responses. Results: The survey was completed by 505 respondents (mean age 58.8 years; 55.2% women). Most tumors were located in the breast (26.5%), digestive system (20.8%), and lung (14.5%). Altogether 97.8% of patients experienced fatigue while receiving chemotherapy. Fatigue treatment was discussed with the oncologist in 72.9% of the cases while only 61.2% of patients reported receiving treatment for fatigue. Fatigue impact on emotional well-being was 54.9 (SD: 19.2). Over 65% of the patients felt that at least 50% of the time, fatigue prevented them from participating in social activities, in about 60% of patients, fatigue prevented their daily activities. Independent of sex or tumor type, fatigue was remembered as the most bothersome symptom of cancer. Conclusions: Fatigue has substantial emotional and social impact on cancer patients and is perceived by patients as the symptom that causes greatest impairment to their daily activities. No significant financial relationships to disclose.
Rheumatoid Arthritis Naive T Cells Share Hypermethylation Sites With Synoviocytes
Authors: Brooke Rhead, Calliope Holingue, Michael Cole, Xiaorong Shao, Hong L. Quach, Diana Quach, Khooshbu Shah, Elizabeth Sinclair, John Graf, Thomas Link, Ruby Harrison, Elior Rahmani, Eran Halperin, Wei Wang, Gary S. Firestein, Lisa F. Barcellos, Lindsey A. Criswell
Journal: Arthritis & Rheumatology (2016)

To determine whether differentially methylated CpGs in synovium-derived fibroblast-like synoviocytes (FLS) of patients with rheumatoid arthritis (RA) were also differentially methylated in RA peripheral blood (PB) samples.For this study, 371 genome-wide DNA methylation profiles were measured using Illumina HumanMethylation450 BeadChips in PB samples from 63 patients with RA and 31 unaffected control subjects, specifically in the cell subsets of CD14+ monocytes, CD19+ B cells, CD4+ memory T cells, and CD4+ naive T cells.Of 5,532 hypermethylated FLS candidate CpGs, 1,056 were hypermethylated in CD4+ naive T cells from RA PB compared to control PB. In analyses of a second set of CpG candidates based on single-nucleotide polymorphisms from a genome-wide association study of RA, 1 significantly hypermethylated CpG in CD4+ memory T cells and 18 significant CpGs (6 hypomethylated, 12 hypermethylated) in CD4+ naive T cells were found. A prediction score based on the hypermethylated FLS candidates had an area under the curve of 0.73 for association with RA case status, which compared favorably to the association of RA with the HLA-DRB1 shared epitope risk allele and with a validated RA genetic risk score.FLS-representative DNA methylation signatures derived from the PB may prove to be valuable biomarkers for the risk of RA or for disease status.
Comparison of Cord Blood and Bone Marrow Mononuclear Cells by Serial Analysis of Gene Expression (SAGE).
Authors: Angela C. Luzo, Adriana S. Duarte, Anderson F. Cunha, Dulcineia M. Albuquerque, Barbara C. Monte-Mor, Gustavo Lacerda, Tarcisio S. Peres, Fernando F. Costa, Sara T. Saad
Journal: Blood (2004)
GW27-e0997 Effect of NOD1/RIP2 signaling pathway on cardiovascular remodeling in hypertensive rats
Authors: Fang Bingqian, Liang Hou, Yingjin Lu, Jinli Liu, Wei Liu, Xiuzhen Zhang, Xu Cheng, Jingjie Chang, Lingmin Sun, Xiuli Wang, Yanchun Ding
Journal: Journal of the American College of Cardiology (2016)
National Library of Medicine May Receive Funding Boost
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.
Authors: Giles Best, Anne Gardiner, Rachel Ibbotson, Aneela Majid, Renata Walewska, Belinda Austen, Tanja Stankovic, Martin Dyer, David Graham Oscier
Journal: Blood (2006)
Relationship between Optical Coherence Tomography Angiography Vessel Density and Severity of Visual Field Loss in Glaucoma
Authors: Adeleh Yarmohammadi, Linda M. Zangwill, Alberto Diniz-Filho, Min Hee Suh, Siamak Yousefi, Luke J. Saunders, Akram Belghith, Patricia Isabel C. Manalastas, Felipe A. Medeiros, Robert N. Weinreb
Journal: Ophthalmology (2016)
Cholera threatens Haiti after Hurricane Matthew
Authors: Susana Ferreira
Journal: BMJ (2016)

A week after Hurricane Matthew ripped through Haiti’s southern peninsula, local authorities claim that there have been 372 deaths, although unofficial figures in the media put the number at more than twice this.

Roads and bridges were severely damaged by the hurricane, and mobile phone and radio towers were destroyed, effectively cutting off many communities for several days. As rescue workers and state authorities reach the hardest hit villages, a more complete picture of the devastation is expected to emerge.

The category 4 hurricane made landfall on 4 October, and as well as damaging infrastructure it …
Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors
Authors: Mayuko Furuta, Masaki Ueno, Akihiro Fujimoto, Shinya Hayami, Satoru Yasukawa, Fumiyoshi Kojima, Koji Arihiro, Yoshiiku Kawakami, Christopher P. Wardell, Yuichi Shiraishi, Hiroko Tanaka, Kaoru Nakano, Kazuhiro Maejima, Aya Sasaki-Oku, Naoki Tokunaga, Keith A. Boroevich, Tetsuo Abe, Hiroshi Aikata, Hideki Ohdan, Kunihito Gotoh, Michiaki Kubo, Tatsuhiko Tsunoda, Satoru Miyano, Kazuaki Chayama, Hiroki Yamaue, Hidewaki Nakagawa
Journal: Journal of Hepatology (2016)
TCT-772 Transcatheter Perivascular Alcohol Denervation with the Peregrine™ System Infusion Catheter: Results from The Peregrine First-In-Human Study
Authors: Adrian A. Ebner, Santiago Gallo, Yoshiaki Mitsutake, Wook Bum Pyun, Fumiaki Ikeno, Laura A. Minarsch, Felix Vega, Nicole Haratani, Vartan E. Ghazarossian, Tim Fischell
Journal: Journal of the American College of Cardiology (2015)
TCT-362 Assessment of Bioresorbable Scaffold With a Novel High-Definition 60MHz IVUS Imaging System: Comparison With Conventional 40MHz IVUS and Optical Coherence Tomography
Authors: Kozo Okada, Hideki Kitahara, Yoshiaki Mitsutake, Shigemitsu Tanaka, Paul Yock, Peter J. Fitzgerald, Fumiaki Ikeno, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2015)
TCT-325 Proper balloon sizing for optimal bridging aortic valvuloplasty therapy in patients awaiting Transcatheter Aortic Valve Replacement
Authors: Janakkumar Kansagra, Dee Dee Wang, Heidar Arjomand, Shawn E. Flynn, Milan Pantelic, Thomas Song, Meredith G. Mahan, Adam Greenbaum, William W. O'Neill
Journal: Journal of the American College of Cardiology (2015)
Prolonged survival and time to disease progression with zoledronic acid in patients with bone metastases from non-small cell lung cancer.
Authors: N. Karamanos, K. Zarogoulidis, E. Boutsikou, P. Zarogoulidis, T. Kontakiotis
Journal: Journal of Clinical Oncology (2010)

e18077 Background: We previously reported that patients (pts) with bone metastases (mets) from non-small cell lung cancer (NSCLC) treated with zoledronic acid (ZOL) in addition to chemotherapy (CHT) had prolonged overall survival (OS) and time to disease progression (TTP) versus CHT alone (p < 0.01 for both; Zarogoulidis K, et al. Int J Cancer. 2009). However, the ZOL benefits reported were not adjusted for baseline covariates, and response rates at bone and primary sites were not separated. Methods: Pts with NSCLC and bone mets were assigned to treatment with CHT (docetaxel 100 mg/m2 + carboplatin AUC 6 q mo) alone if asymptomatic or CHT + ZOL (4 mg q mo) for bone pain. Disease responses (complete, partial, stable, or progressive) were assessed at bone and primary sites. The effects of treatment on OS and TTP were assessed by Cox regression in multivariate (MV) models controlling for type of bone lesions, sex, radiotherapy, and line of chemotherapy. Results: Of 144 enrolled pts, 57 received CHT alone, and 87 received CHT + ZOL. After completion of first-line CHT by all pts, the estimated rate of partial response in the primary tumor site was 2-fold higher for ZOL (32% vs 16% of pts for CHT alone), and the rate of progressive disease in bone was a relative 38% lower for ZOL (23% vs 37% of pts for CHT alone). The MV model confirmed the significantly increased median OS for CHT + ZOL vs CHT-alone pts that was detected in Kaplan-Meier (KM) analyses (median OS of 578 vs 384 d, respectively; p < 0.001). The ZOL-treated pts had a significant 39% reduced risk of death vs the CHT-alone pts (HR = 0.607; p = 0.015). Similarly, the MV model confirmed the significantly increased TTP in the CHT + ZOL vs CHT-alone pts that was detected in KM analyses (median TTP of 265 vs 150 d, respectively, p < 0.001). The ZOL-treated pts had a profound 61% reduced risk of disease progression vs the CHT-alone pts (HR = 0.392; p < 0.001). Conclusions: These analyses confirm previous results that pts with bone pain who received ZOL had superior disease progression and survival outcomes vs CHT alone in pts with asymptomatic bone mets from NSCLC. Moreover, the higher response rates in the primary tumor site with CHT + ZOL vs CHT alone suggest direct ZOL anticancer activity. No significant financial relationships to disclose.
Splenic radiation during pancreatic cancer radiotherapy: Are we throwing the baby out with the bath water?
Authors: Awalpreet Singh Chadha, Guan Liu, Harpreet Kaur Arora, Howard D Thames, Sunil Krishnan
Journal: Journal of Clinical Oncology (2016)

354 Background: Lymphopenia is commonly seen following chemoradiation and is associated with a poor prognosis. We conducted this study to determine if the severity of lymphopenia is dependent on the radiation dose and the fractional volume of spleen irradiated unintentionally during definitive chemoradiation in patients with locally advanced pancreatic cancer (LAPC). Methods: 177 patients with LAPC were treated with induction chemotherapy (FOLFIRINOX or gemcitabine- based regimens) followed by chemoradiation (CRT; median 50.4 Gy with concurrent capecitabine) from 1/2006 to 12/2012. Absolute lymphocyte count (ALC) was recorded at baseline, prior to CRT and 2-10 weeks after the end of CRT. Splenic dose-volume histogram (DVH) parameters were reported as mean splenic dose (MSD) and the percentage of splenic volume receiving at least 5 Gy (V5), 10 Gy (V10), 15 Gy (V15) and 20 Gy (V20) dose. Overall survival (OS) was analyzed using Cox model and multivariate logistic regression was used to assess the development of post CRT severe lymphopenia (ALC &lt; 0.5 K/UL) using baseline and treatment factors. Results: Median post-CRT ALC (0.68 K/UL, range 0.13 to 2.72) was significantly lower than both baseline (1.42 K/UL, range 0.34- 3.97; p &lt; 0.0001) and pre-CRT ALC (1.32 K/UL, range 0.36- 4.82; p &lt; 0.0001). Post-CRT ALC &lt; 0.5 K/UL was associated with inferior OS on univariate (16.8 vs. 21.2 months, p = 0.004) and multivariate analysis (HR = 1.9, p = 0.002).The MSD was 8.8 Gy and log MSD showed a significant negative correlation (r = -0.18, p = 0.02) with post-CRT ALC. Median V5, V10, V15 and V20 were 34%, 21%, 13% and 8% respectively. Median V10 (32.6 vs. 16%, p = 0.04), V15 (23.2 vs. 9.5%, p = 0.03) and V20 (15.4 vs. 4.6%, p = 0.02) were significantly higher in patients with severe lymphopenia. On multivariate logistic regression analysis, baseline lymphopenia (ALC &lt; 1 K/UL; p = 0.003, OR = 4.6) and MSD (p = 0.03, OR = 7.3) were independent predictors for the development of severe post-CRT lymphopenia. Conclusions: LAPC patients receiving high MSD during CRT are at increased risk of developing severe lymphopenia, which is an independent predictor of poor OS. Routine assessment of splenic DVHs prior to acceptance of treatment plans may minimize this risk.
JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera.
Authors: Anthony Green, Peter Campbell, Linda Scott, Georgina Buck, Keith Wheatley, Clare East, Joanne Marsden, Audrey Duffy, Elaine Boyd, Anthony Bench, Mike Scott, George Vassiliou, Don Milligan, Steve Smith, Wendy Erber, David Bareford, Bridget Wilkins, John Reilly, Claire Harrison
Journal: Blood (2005)
Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.
Authors: Adolfo de la Fuente, Antonio Salar, Carlos Panizo, Belen Navarro, Teresa Olave, María Jesus Peñarrubia, JoaquÃn Herrero, Jose Francisco Tomas, Miguel Canales, Eva González-Barca
Journal: Blood (2009)
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism
Authors: Maria New, Semira Sheikh, Mina Bekheet, Heidi Olzscha, Marie-Laetitia Thezenas, Matthew A. Care, Susan Fotheringham, Reuben M. Tooze, Benedikt Kessler, Nicholas B. La Thangue
Journal: Cancer Research (2016)

Histone deacetylase (HDAC) inhibitors have proven useful therapeutic agents for certain hematologic cancers. However, HDAC inhibition causes diverse cellular outcomes, and identification of cancer-relevant pathways within these outcomes remains unresolved. In this study, we utilized an unbiased loss-of-function screen and identified the Toll-like receptor (TLR) adaptor protein MYD88 as a key regulator of the antiproliferative effects of HDAC inhibition. High expression of MYD88 exhibited increased sensitivity to HDAC inhibitors; conversely, low expression coincided with reduced sensitivity. MYD88-dependent TLR signaling controlled cytokine levels, which then acted via an extracellular mechanism to maintain cell proliferation and sensitize cells to HDAC inhibition. MYD88 activity was directly regulated through lysine acetylation and was deacetylated by HDAC6. MYD88 was a component of a wider acetylation signature in the ABC subgroup of diffuse large B-cell lymphoma, and one of the most frequent mutations in MYD88, L265P, conferred increased cell sensitivity to HDAC inhibitors. Our study defines acetylation of MYD88, which, by regulating TLR-dependent signaling to cytokine genes, influences the antiproliferative effects of HDAC inhibitors. Our results provide a possible explanation for the sensitivity of malignancies of hematologic origin to HDAC inhibitor-based therapy. Cancer Res; 76(23); 6975-87. ©2016 AACR.
Serum alkaline phosphatase levels in men with prostate cancer treated with a gonadotropin-releasing hormone agonist or antagonist.
Authors: Bo-Eric Persson, E. David Crawford, Anders Malmberg, Anders Neijber
Journal: Journal of Clinical Oncology (2015)

e16044 Background: Androgen-deprivation therapy leads to decreased bone mineral density and increased fracture risk. Increased serum alkaline phosphatase (S-ALP) is associated with progression of skeletal metastases and may predict disease progression and death. We report further analyses of S-ALP from studies comparing gonadotropin-releasing hormone (GnRH) agonists with the antagonist, degarelix. Methods: S-ALP was prospectively measured in men with metastatic disease in two randomised trials: CS21 (men were randomised to leuprolide 7.5 mg [n = 201] or degarelix 240/80 mg [n = 207]) and CS35 (goserelin 3.6/10.8 mg [n = 275] or degarelix 240/480 mg [n = 550]). A pooled analysis of five phase III/IIIb randomised trials comparing GnRH agonists and degarelix analysed skeletal adverse events. Results: Pooled analysis in metastatic patients suggested a faster suppression of S-ALP to levels below baseline with a GnRH antagonist (day 56) vs GnRH agonists (day 84). Over 1 year, S-ALP levels were significantly lower with degarelix (p = 0.037). Patients in CS21/21A with baseline metastatic disease had significantly lower S-ALP values at day 364 if treated with degarelix (96 IU/L; n = 37) vs leuprolide (179 IU/L; n = 47), p = 0.013. Mean S-ALP levels returned to baseline 177 days later with degarelix compared with leuprolide. In study CS35, bone pain was reduced in GnRH antagonist-treated men (p = 0.001). In the pooled analysis, fracture risk was lower with a GnRH antagonist (HR = 0.42, 95% CI 0.16–1.05); this reached significance in men with testosterone > 2 ng/mL at baseline (GnRH antagonist vs GnRH agonists HR = 0.32, 95% CI 0.12–0.89; p = 0.028). Conclusions: These data indicate that for men with metastatic prostate cancer, S-ALP suppression to below baseline occurs more quickly and for longer with a GnRH antagonist vs GnRH agonists. Reduced bone pain and a lower incidence of fractures suggests better control of skeletal disease. Follicle stimulating hormone regulates bone resorption and is suppressed to a greater degree with a GnRH antagonist vs GnRH agonists, providing a potential mechanism to explain these findings.
Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer
Authors: Oladunni O. Akin-Akintayo, Ashesh B. Jani, Oluwaseun Odewole, Funmilayo I. Tade, Peter T. Nieh, Viraj A. Master, Leah M. Bellamy, Raghuveer K. Halkar, Chao Zhang, Zhengjia Chen, Mark M. Goodman, David M. Schuster
Journal: Clinical Nuclear Medicine (2016)

We explored the influence of FACBC (fluciclovine) PET/CT on the decision to offer radiotherapy and radiotherapy treatment field recommendations in postprostatectomy patients with recurrent prostate cancer.After obtaining institutional review board approval and informed consent, 87 patients with detectable prostate-specific antigen (PSA) levels were recruited into a prospective clinical trial. After an initial provider-determined radiotherapy plan based on conventional imaging, 44 of 87 patients were randomized to additionally undergo fluciclovine PET/CT. Pre- and post-fluciclovine radiotherapy decisions were compared and changes were noted. Statistical significance of these decision changes was determined.Two of 44 patients in the experimental arm dropped out before fluciclovine scanning. Thirty-four (81.0%) of 42 had positive results on fluciclovine. Overall radiotherapy decision was changed in 17 (40.5%) of 42. Mean PSA, original Gleason score, and prostatectomy-PET interval did not differ significantly between patients with and without radiotherapy decision changes. Two (4.8%) of 42 had the decision for radiotherapy withdrawn due to positive extrapelvic findings. Radiotherapy field decision was changed in 15 (35.7%) of 42. Eleven (73.3%) of 15 had fields changed from prostate bed only to both prostate bed and pelvis, while 4 (26.7%) of 15 had fields changed from both prostate bed and pelvis to prostate bed only. Changes in overall radiotherapy decision and field were statistically significant (P < 0.0001). However, the change in the decision to offer radiotherapy or not was not statistically significant (P = 0.15).Fluciclovine PET/CT significantly changed radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer. Further work in determining differences in PSA-free survival is ongoing.